Charts
|
ACW |
Re:
ACW Chart Thread
|
|
US10
|
138 |
58K |
24 |
31/07/24 |
31/07/24 |
Charts
|
138
|
58K
|
24
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Application for quotation of securities - ACW
|
|
US10
|
25 |
7.8K |
14 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
25
|
7.8K
|
14
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW CEO presentation Sachs Neuroscience and JPM week
|
|
US10
|
20 |
9.3K |
19 |
09/01/23 |
09/01/23 |
ASX - By Stock
|
20
|
9.3K
|
19
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW announces positive Alzheimers Disease clinical results
|
|
US10
|
79 |
29K |
27 |
11/10/22 |
11/10/22 |
ASX - By Stock
|
79
|
29K
|
27
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW announces Phase 2 trial designs for AD & MDD
|
|
US10
|
9 |
5.2K |
12 |
18/06/22 |
18/06/22 |
ASX - By Stock
|
9
|
5.2K
|
12
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW announces positive XanaMIA results for Xanamem
|
|
US10
|
33 |
17K |
22 |
27/04/22 |
27/04/22 |
ASX - By Stock
|
33
|
17K
|
22
|
|
ASX - By Stock
|
ACW |
Re:
Momentum & Belief
|
|
US10
|
48 |
23K |
17 |
23/02/22 |
23/02/22 |
ASX - By Stock
|
48
|
23K
|
17
|
|
ASX - By Stock
|
ACW |
Re:
Ann: New clinical advisory boards
|
|
US10
|
15 |
6.7K |
2 |
24/12/21 |
24/12/21 |
ASX - By Stock
|
15
|
6.7K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: New clinical advisory boards
|
|
US10
|
15 |
6.7K |
6 |
24/12/21 |
24/12/21 |
ASX - By Stock
|
15
|
6.7K
|
6
|
|
ASX - By Stock
|
ACW |
Re:
Ann: New clinical advisory boards
|
|
US10
|
15 |
6.7K |
10 |
18/12/21 |
18/12/21 |
ASX - By Stock
|
15
|
6.7K
|
10
|
|
ASX - By Stock
|
ACW |
Re:
Ann: New clinical advisory boards
|
|
US10
|
15 |
6.7K |
10 |
12/12/21 |
12/12/21 |
ASX - By Stock
|
15
|
6.7K
|
10
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Trading Halt
|
|
US10
|
45 |
17K |
9 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
45
|
17K
|
9
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Trading Halt
|
|
US10
|
45 |
17K |
8 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
45
|
17K
|
8
|
|
ASX - By Stock
|
ACW |
Momentum & Belief
|
|
US10
|
48 |
23K |
26 |
06/11/21 |
06/11/21 |
ASX - By Stock
|
48
|
23K
|
26
|
|
ASX - By Stock
|
ACW |
Re:
Xanamem reduces cortisol
|
|
US10
|
33 |
16K |
14 |
28/09/21 |
28/09/21 |
ASX - By Stock
|
33
|
16K
|
14
|
|
ASX - By Stock
|
ACW |
Re:
Xanamem reduces cortisol
|
|
US10
|
33 |
16K |
12 |
21/09/21 |
21/09/21 |
ASX - By Stock
|
33
|
16K
|
12
|
|
ASX - By Stock
|
ACW |
Re:
Valuing An Early Stage Pharma
|
|
US10
|
40 |
14K |
3 |
22/06/21 |
22/06/21 |
ASX - By Stock
|
40
|
14K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Valuing An Early Stage Pharma
|
|
US10
|
40 |
14K |
18 |
17/06/21 |
17/06/21 |
ASX - By Stock
|
40
|
14K
|
18
|
|
ASX - By Stock
|
ACW |
Valuing An Early Stage Pharma
|
|
US10
|
40 |
14K |
26 |
06/05/21 |
06/05/21 |
ASX - By Stock
|
40
|
14K
|
26
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Strategic Update Teleconference Transcript
|
|
US10
|
108 |
23K |
9 |
01/05/21 |
01/05/21 |
ASX - By Stock
|
108
|
23K
|
9
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Resignation of Dr Bill Ketelbey as Chief Executive Officer
|
|
US10
|
164 |
57K |
7 |
09/03/21 |
09/03/21 |
ASX - By Stock
|
164
|
57K
|
7
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Resignation of Dr Bill Ketelbey as Chief Executive Officer
|
|
US10
|
164 |
57K |
4 |
09/03/21 |
09/03/21 |
ASX - By Stock
|
164
|
57K
|
4
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Resignation of Dr Bill Ketelbey as Chief Executive Officer
|
|
US10
|
164 |
57K |
2 |
08/03/21 |
08/03/21 |
ASX - By Stock
|
164
|
57K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Resignation of Dr Bill Ketelbey as Chief Executive Officer
|
|
US10
|
164 |
57K |
4 |
08/03/21 |
08/03/21 |
ASX - By Stock
|
164
|
57K
|
4
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Resignation of Dr Bill Ketelbey as Chief Executive Officer
|
|
US10
|
164 |
57K |
6 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
164
|
57K
|
6
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Resignation of Dr Bill Ketelbey as Chief Executive Officer
|
|
US10
|
164 |
57K |
9 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
164
|
57K
|
9
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Resignation of Dr Bill Ketelbey as Chief Executive Officer
|
|
US10
|
164 |
57K |
20 |
09/02/21 |
09/02/21 |
ASX - By Stock
|
164
|
57K
|
20
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Review of 2020 and outlook
|
|
US10
|
59 |
21K |
18 |
26/01/21 |
26/01/21 |
ASX - By Stock
|
59
|
21K
|
18
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen Presentation & Planned Conference Call
|
|
US10
|
31 |
5.7K |
11 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
31
|
5.7K
|
11
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen Medical Investor Presentation
|
|
US10
|
58 |
18K |
10 |
08/10/20 |
08/10/20 |
ASX - By Stock
|
58
|
18K
|
10
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen Medical Investor Presentation
|
|
US10
|
58 |
18K |
14 |
07/10/20 |
07/10/20 |
ASX - By Stock
|
58
|
18K
|
14
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
US10
|
80 |
28K |
21 |
09/05/20 |
09/05/20 |
ASX - By Stock
|
80
|
28K
|
21
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
US10
|
80 |
28K |
25 |
08/05/20 |
08/05/20 |
ASX - By Stock
|
80
|
28K
|
25
|
|
ASX - By Stock
|
ACW |
Re:
Vienna AAT-AD/PD™ 2020 conference and COVID-19
|
|
US10
|
44 |
20K |
3 |
25/03/20 |
25/03/20 |
ASX - By Stock
|
44
|
20K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Additional R&D Tax Incentive rebate received
|
|
US10
|
52 |
31K |
12 |
21/02/20 |
21/02/20 |
ASX - By Stock
|
52
|
31K
|
12
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen at SACHS Forum and JP Morgan week
|
|
US10
|
53 |
30K |
11 |
12/01/20 |
12/01/20 |
ASX - By Stock
|
53
|
30K
|
11
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Managing Director's AGM Presentation
|
|
US10
|
89 |
33K |
8 |
05/12/19 |
05/12/19 |
ASX - By Stock
|
89
|
33K
|
8
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Managing Director's AGM Presentation
|
|
US10
|
89 |
33K |
3 |
03/12/19 |
03/12/19 |
ASX - By Stock
|
89
|
33K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
The Science Behind Actinogen
|
|
US10
|
60 |
33K |
11 |
24/11/19 |
24/11/19 |
ASX - By Stock
|
60
|
33K
|
11
|
|
ASX - By Stock
|
ACW |
Re:
@US10 silence since XanaHES announcement
|
|
US10
|
210 |
85K |
9 |
07/11/19 |
07/11/19 |
ASX - By Stock
|
210
|
85K
|
9
|
|
ASX - By Stock
|
ACW |
Re:
@US10 silence since XanaHES announcement
|
|
US10
|
210 |
85K |
39 |
31/10/19 |
31/10/19 |
ASX - By Stock
|
210
|
85K
|
39
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Appendix 4E & Annual Report
|
|
US10
|
49 |
34K |
20 |
26/08/19 |
26/08/19 |
ASX - By Stock
|
49
|
34K
|
20
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Xanamen Clinical Development & Investor Update
|
|
US10
|
59 |
15K |
9 |
29/06/19 |
29/06/19 |
ASX - By Stock
|
59
|
15K
|
9
|
|
ASX - By Stock
|
ACW |
Re:
Ann: XanaHES Trial to Continue
|
|
US10
|
36 |
15K |
20 |
30/05/19 |
30/05/19 |
ASX - By Stock
|
36
|
15K
|
20
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Phase II Alzheimer's Disease Trial - results
|
|
US10
|
455 |
144K |
11 |
17/05/19 |
17/05/19 |
ASX - By Stock
|
455
|
144K
|
11
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Phase II Alzheimer's Disease Trial - results
|
|
US10
|
455 |
144K |
5 |
14/05/19 |
14/05/19 |
ASX - By Stock
|
455
|
144K
|
5
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Phase II Alzheimer's Disease Trial - results
|
|
US10
|
455 |
144K |
24 |
12/05/19 |
12/05/19 |
ASX - By Stock
|
455
|
144K
|
24
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Trading Halt
|
|
US10
|
133 |
49K |
7 |
05/05/19 |
05/05/19 |
ASX - By Stock
|
133
|
49K
|
7
|
|
ASX - By Stock
|
ACW |
Re:
Ann: DSMB again reaffirms XanADu trial to continue without change
|
|
US10
|
51 |
11K |
10 |
24/04/19 |
24/04/19 |
ASX - By Stock
|
51
|
11K
|
10
|
|
ASX - By Stock
|
ACW |
Re:
Edison TV
|
|
US10
|
85 |
24K |
13 |
14/04/19 |
14/04/19 |
ASX - By Stock
|
85
|
24K
|
13
|
|